ArticleASN neuro2026
Proteomic Characterization of Spinal Cord Myelin in the Mouse.
Article in ASN neuro, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The myelin proteome is a critical structural and functional component of the central nervous system (CNS), undergoing dynamic remodeling throughout life. Pathological changes, such as those in multiple sclerosis, disrupt myelin integrity and lead to severe neurological deficits. Establishing a reproducible baseline of the CNS myelin proteome is therefore essential for monitoring alterations in disease models. Here, we present a comprehensive proteomic dataset of purified spinal cord myelin from healthy mice. Myelin fractions were isolated by preparative sucrose density centrifugation, followed by gel-free peptide separation and mass spectrometric analysis. Label-free quantification based on at least two tryptic peptides identified 725 proteins across six spinal cord samples. Comparison with previous large-scale datasets confirmed the robustness of our workflow. In particular, our dataset showed a 71% overlap with the 809 proteins identified by Jahn et al. using a highly similar proteomic approach. Importantly, there was near-complete agreement for canonical myelin proteins, validating both the specificity and reproducibility of our method. Beyond this shared core, our dataset contributed additional proteins, including axon- and glia-associated candidates, expanding the baseline repertoire of the spinal cord myelin proteome. In summary, this study establishes and validates a reliable workflow for spinal cord myelin proteomics and provides a reproducible reference dataset. While not yet including diseased tissue, this baseline is directly applicable to experimental models of demyelination and remyelination, offering a critical foundation for detecting and interpreting disease-related proteomic alterations in multiple sclerosis research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.